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0929-6646/Copyright ª 2015, ElsevierBackground/Purpose: Cytotoxic chemotherapy via central venous access ports is an important
part of the standard treatment for most cancers, but it is accompanied with the risk of infec-
tions. This study aimed to analyze the incidence and risk factors for central venous access
port-related infection (CPI) among Chinese patients receiving cytotoxic chemotherapy.
Methods: Between January 1, 2002 and December 31, 2005 a total of 1391 cancer patients with
1449 totally implantable central venous access ports were evaluated. The log-rank test and
Cox proportional hazards model were used for the analyses of risk factors.
Results: The overall CPI incidence rate was 0.21 per 1000 catheter-days. Hematological malig-
nancies and head and neck cancer were associated with an increased risk of CPI (hazard ratio
4.00 and 4.11, respectively, both p < 0.001) and less infection-free catheter longevity
(p < 0.001) compared with other cancer types. Chemotherapy in an adjuvant setting was asso-
ciated with a lower risk of infection than for patients in a nonadjuvant setting (p < 0.001). The
most common pathogens isolated from CPI were Pseudomonas aeruginosa and Candida.
Conclusion: Infection remains to be a challenging issue for totally implantable central venous
ports. Implementation of an insertion bundle for the prevention of central line-associated blood-
stream infections is warranted, especially for those patients with hematological and head and
neck cancers, as well as for patients receiving chemotherapy in the metastatic settings.
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1056 T.-Y. Wang et al.IntroductionCytotoxic chemotherapy is an important part of the standard
treatment for most cancers. To avoid frequent venipunc-
tures, which are increasingly difficult after multiple courses
of chemotherapy, and to facilitate the administration of
continuous infusional chemotherapy, it is common to insert
totally implantable central venous access ports.1,2 However,
central port-related bacteremia and fungemia, including
catheter tunnel infection, pocket infection in port devices,
and skin-site infection, remain a challenging issue for clini-
cians. The incidence rate of central port-related infections
(CPI) has been reported to vary from 7% to 19%.3,4 Many risk
factors for CPI have been reported, including hematological
malignancy, neutropenia, chronic steroid use, lacking peri-
operative antibiotic use, pancreatic cancer, poor perfor-
mance status, previous infection, parenteral nutrition,
immediate palliative care after implantation, and an inex-
perienced surgeon.5e8 Considering the evolution of new
materials in the make-up of central port devices, and pro-
longed cancer survival resulting in longer period of chemo-
therapy, it is possible that the incidence of CPI and
associated risk factors have changed. The aim of this study
was to examine the incidence and risk factors for CPI among
Chinese patients receiving cytotoxic chemotherapy.
Methods
Patient population and implanted devices
Between January 1, 2002 and December 31, 2005 a total of
1391 cancer patients receiving 1449 totally implantable
central venous access ports at Chang Gung Memorial Hos-
pital, Chiayi, Taiwan were evaluated. All the devices had
been used for at least one cycle of intravenous antineo-
plastic chemotherapy administration. Electronic medical
records provided patient age, sex, disease status, primary
tumor location, chemotherapy setting, time of catheter
insertion, and the cause of catheter failure. All patients
were followed up until death, last port removal, or until
December 31, 2006, whichever camefirst. Port implantation
was performed by well-trained surgeons in the operating
room. The catheter tip was inserted in the superior vena
cava under fluoroscopic guidance. Local anesthesia (10 mL
of 2% mepivacaine hydrochloride) was administered for
most patients during the implantation of the central venous
access ports. General anesthesia was used only when a
central port was implanted in conjunction with another
major surgery. Prophylactic perioperative antibiotics (a
single dose of cefazolin) was administered routinely. The
surgical approach was either cephalic cut-down or subcla-
vian vein puncture on either side, depending on the sur-
geon’s preference. Implantation from the jugular or femoral
vein system was performed only when the cephalic and
subclavian vein systems failed. The port was fixed to the
underlying pectoral muscle fascia with a single, nonab-
sorbable suture. Filling of the port system with diluted
heparin saline was performed at the end of each procedure.
The port was routinely flushedwith diluted heparin saline by
trained oncology nurses, following the administration of
chemotherapy agents. The device was then maintained byflushing with a heparinized solution every 4e8 weeks
without using any prophylactic antibiotics. Noncoring Huber
needles were utilized for all injections.
Central port-related infection (CPI) and risk factors
Bloodcultureswerecollected fromportandperipheral veins in
patientswho had clinical symptoms or signs of infection (fever
> 38C, chills, or leukocytosis). A diagnosis of CPI was made
based on at least one set of positive blood cultures from the
catheter tip upon removal, > 10-fold increase in colony-
forming units (CFU) per mL of blood aspirated from the port in
comparison to peripheral blood cultures, or > 1000 CFUs of
bacteria cultured through the device in the absence of pe-
ripheral blood cultures. In addition, clinical signs such as local
cutaneous erythema, induration, or purulent discharge from
theportpocket,and resolutionof feveror sepsisaftercatheter
removal also suggested CPI despite a negative culture.9e13 All
occurrences of CPIwere stratified bypatient age, sex, primary
tumor type, and chemotherapy setting. Chemotherapy set-
tingsweredivided into twogroups, adjuvantandnonadjuvant.
Adjuvant settings included ports for adjuvant chemotherapy
(chemotherapies given after main treatment, such as curative
surgery or concurrent chemoradiotherapy with the goal to
prevent recurrence) and neo-adjuvant chemotherapy (che-
motherapies given before main treatment with the goal to
reduce tumor size or prevent tumor spreading). Ports for
chemotherapy for metastatic disease or other curative intent
were regarded as nonadjuvant. Catheter longevity was
defined as the number of days the device remained in situ and
the time from catheter insertion until removal due to infec-
tion, vessel or device thrombosis, device breakage, the
completion of chemotherapy (in adjuvant and curative set-
tings), death, or until December 31, 2006. Incidence of CPIwas
estimated as the number of infectious episodes per 1000
catheter-days. Infection-free catheter longevity was defined
as the duration between port implantation and the develop-
ment of an infection or last follow-up date.
Statistical analysis
Continuous variables were presented as mean  standard
deviation. The number of days for which a catheter remained
in place was expressed as themedian with the standard error
due to censoring. The log-rank test and Pearson’s Chi-square
test was used to evaluate differences in catheter longevity
and infection rate between sexes, types of malignancy, and
chemotherapy settings. The Cox proportional hazards model
was used to simultaneously examine all risk factors. A p
value < 0.05 indicated statistical significance. All statistical
analyses were performed using IBM SPSS 19 software (IBM
Corp. Released 2010. IBM SPSS Statistics forWindows, Version
19.0. Armonk, NY: IBM Corp.).
Results
Incidence of CPI among primary malignancies
A total of 1449 central venous access ports were implanted
in 1391 patients, including 1288 solid tumors (93%) and 103








All 1449 (100) 149 (10.3)
Sex
Male 899 (62) 96 (10.7) 0.53
Female 550 (38) 53 (9.6)
Type of malignancy
Hematological 75 (5) 34 (45.3) < 0.001
Solid 1225 (95) 115 (9.4)
Chemotherapy setting
Adjuvant 205 (14) 11 (5.1) 0.006
Metastatic 837 (63) 70 (7.7) < 0.001
Others 258 (23) 68 (20.9)
a Pearson’s Chi-square test.
Table 3 Univariate and multivariate analyses for risk
factors of central port-related infection.
Univariate Multivariate
HR p HR p
Age
 60 y 1 0.033 1 0.863
> 60 y 0.70 1.03
Sex
Female 1 0.035 1 0.402
Male 1.34 1.19
Location of primary tumor
Colorectal 1 1
Lung 1.85 0.043 1.35 0.335
Head & neck 5.94 < 0.001 4.11 < 0.001
Breast 1.41 0.370 1.78 0.159
Gastric 1.30 0.674 0.96 0.949
Hematogenous 7.24 < 0.001 4.00 < 0.001
HeBeP 2.97 0.009 2.49 0.084
Esophageal 2.76 0.063 1.80 0.301
Urological 1.25 0.763 0.95 0.945
Gynecological 11.32 <0.001 13.55 < 0.001
Others 3.47 0.003 2.69 0.019
Chemotherapy setting
Nonadjuvant 1 <0.001 1 < 0.001
Adjuvant 0.26 0.26
Bold denotes statistical significance.
HeBeP Z hepatobiliary and pancreatic; HR Z hazard ratio.
Incidence and risk factors of CPI in cancer patients 1057hematological malignancies (7%), for at least one cycle of
intravenous chemotherapy between January 1, 2002 and
December 31, 2005. Taken together, there were 899 port
implantations in 862 male patients (62%) and 550 port im-
plantations in 529 female patients (38%). Forty-seven pa-
tients had more than one port implantation. The median
patient follow-up time was 17.3 months [95% confidence
interval (CI) 16.7e18.0 months]. The mean age was
59.8  13.1 years (range, 13e91 years). The median cath-
eter longevity was 16.6 months (95% CI 16.0e17.3 months)
and total catheter-days were 723,192 catheter-days. As
shown in Table 1, patients with hematological malignancies
had a higher incidence of CPI compared with patients with
solid tumors. Chemotherapy in nonadjuvant settings was
associated with a higher incidence of CPI compared with
adjuvant settings. The overall CPI incidence was 0.21 per
1000 catheter-days (149 catheter infection episodes over
723,192 catheter-days; Table 2). Of these patients, hema-
tological, head and neck, and gynecological cancers were
the three major sites associated with higher risk for CPI
compared with other primary cancers.Table 2 Primary tumor sites and incidences of central port-rel
Malignancy Patient no. (%) Catheter no.
Colorectal 372 (26.7) 379 (26.2)
Lung 343 (24.7) 357 (24.6)
Head and neck 153 (11.0) 162 (11.2)
Breast 110 (7.9) 116 (8.0)
Gastric 76 (5.5) 82 (5.7)
Hematological 103 (7.4) 109 (7.5)
HepatobiliaryePancreatic 83 (6.0) 85 (5.9)
Esophageal 41 (2.9) 43 (3.0)
Urologic 45 (3.2) 45 (3.1)
Gynecologic 12 (0.9) 15 (1.0)
Others 53 (3.8) 56 (3.9)
Total 1391 (100) 1449 (100)
a Central port infection episodes/total catheter numbers.Risk factors for CPI
The univariate analysis revealed possible factors associated
with a higher CPI, these included age, sex, site of the pri-
mary malignancy, and chemotherapy setting. However, in
the multivariate analysis, age and sex were not significant
risk factors. The site of primary malignancy and chemo-
therapy setting remained significant risk factors for CPI.
Patients with head and neck, hematological, and gyneco-








23 (6.1) 267,955 0.09
22 (6.2) 137,336 0.16
31 (19.1) 58,715 0.53
10 (8.6) 82,898 0.12
3 (3.7) 27,101 0.11
34 (31.2) 51,395 0.66
8 (9.4) 30,441 0.26
4 (9.3) 16,926 0.24
2 (4.4) 18,718 0.11
4 (26.7) 4,120 0.97
8 (14.3) 27,587 0.29
149 (10.3) 723,192 0.21
Figure 1 KaplaneMeier curves of infection-free catheter longevity for hematogenous malignancy in comparison with solid tumors
(p < 0.001 by log-rank test).
Figure 2 KaplaneMeier curves of infection-free catheter longevity for head and neck cancer (HNC) in comparison with other
nonhead and neck tumors (nonHNC; p < 0.001 by log-rank test).
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adjuvant chemotherapy had a lower risk for infection than
nonadjuvant setting (p < 0.001; Table 3). Overall, patients
with solid tumors had longer infection-free catheter
longevity compared with those with hematological malig-
nancies (p < 0.001, Figure 1). In solid tumors, head and
neck cancer (HNC) was associated with less infection-free
catheter longevity than nonhead and neck (nonHNC) can-
cers (p < 0.001, Figure 2).
Microorganisms isolated from infected ports and
catheters
In 149 episodes of diagnosed central port-related infection,
Gram-negative bacteria were the most common pathogens
(34.9%), followed by Gram-positive bacteria (16.7%), and
fungi (16.1%). Furthermore, 48 cases (32.2%) diagnosed as
CPI had a negative culture (Table 4). In Gram-negative
bacteria, Pseudomonas aeruginosa (15.4%) and Enter-
obacteriae spp. (12.7%) were the most common pathogens.Table 4 Pathogens cultured from 149 episodes of central
port-related infection.
Organism n %a




Staphylococcus epidermidis 4 2.7
Staphylococcus haemolyticus 2 1.3
Other coagulase-negative 2 1.3
Enterococcus spp. 1 0.7
Others 2 1.3
Gram negative 52 34.9
Pseudomonas aeruginosa 23 15.4
Enterobacteriae spp.
Enterobacter cloacae 10 6.7
Citrobacter freundii 2 1.3
Escherichia coli 2 1.3
Klebsiella pneumoniae 2 1.3
Pantoea 1 0.7
Serratia marcescens 2 1.3




Stenotrophomonas maltophilia 4 2.7
Fungi 24 16.1
Candida spp. 14 9.4
Yeast-like organisms 10 6.7
No organism identified 48 32.2
Total 149 100
MRSA Z methicillin-resistant Staphylococcus aureus;
MSSA Z methicillin-sensitive Staphylococcus aureus.
a Percentage of each organism among total numbers of
catheter-related infection cases.Staphylococcus spp. (14.7%) was the predominant Gram-
positive pathogen. The fungus isolated included Candida
spp. (9.4%) and other yeast-like organisms (6.7%).Discussion
Among the currently evaluated 1391 patients (1449 ports),
the overall incidence rate of CPI was 0.21 per 1000
catheter-days. As reported in the literature, the incidence
of CPI ranged from 0.091 per 1000 catheter-days to 2.77 per
1000 catheter-days,8,14,15 and most of the studies were
retrospective investigations. The variation could be
attributed to differences in the examined patient popula-
tion. For example, a significant increased risk of CPI in
patients with hematological malignancies (hazard ratio
4.00; p < 0.001) and HNC (hazard ratio 4.11; p < 0.001)
compared with patients with colorectal cancer (hazard
ratio Z 1) was observed. Noticeably, hematological ma-
lignancies and HNC were associated with significantly less
infection-free catheter longevity compared with other
cancer types (p < 0.001). In a prospective study, Mollee
et al16 also reported hematological malignancies may
confer a greater risk for CPI than solid tumors. Long dura-
tion of neutropenia,17,18 immunosuppression, and frequent
catheter manipulations were the major risks factors
contributing to the increased risk of CPI in these patients.
There is a paucity of data about port infection in HNC
patients. Bos et al19 recently reported an increased rate of
port infection in patients with HNC compared with nonHNC
(0.68 per 1000 catheter days vs. 0.21 per 1000 catheter
days, respectively, p < 0.001). In the current study, the
rate of infection for HNC patients was similar (0.53 per 1000
catheter days). Unlike hematological cancer, the definite
risk factors for CPI have not been identified in HNC pa-
tients. The authors assume multiple factors may be perti-
nent to the increased risk of infection: (1) HNC patients
undergoing radical surgery and concurrent chemoradiation
usually are associated with malnutrition and impaired im-
mune function. Poor oral intake necessitates the increased
use of parenteral nutrition, further increasing the risk of
blood stream infections; (2) it is noteworthy that patients
with HNC have a higher incidence of infection compared
with patients with other malignancies because microbes
are more likely to colonize in the oral cavity and the skin
surrounding the insertion site;20 and (3) platinum remains
the standard regimen for HNC but has been reported to
carry a high risk of cumulative myelosuppression and
catheter-related systemic infections.21e23 Nevertheless, a
further prospective study is warranted to validate the role
of these factors in central port infections.
It is notable that the incidence of CPI was lower in pa-
tients who were receiving adjuvant/neoadjuvant chemo-
therapy than in those receiving chemotherapy in
nonadjuvant settings. Although the mechanism is unclear,
this observation may be attributable to an early tumor
stage, more integral immunity, and fewer hospitalizations
in patients with adjuvant settings. Pseudomonas aeruginosa
and Candida were the most common pathogens in the
current studyeboth are known to be predominant nosoco-
mial pathogens in hospital settings. Other studies were in
agreement with the current result that Gram-negative
1060 T.-Y. Wang et al.bacteria has become the most common pathogen for CPI in
recent decades.6,12 Staphylococcus supp. was the second
most common pathogen. These Gram-positive cocci are
known to colonize in the skin, yet the association between
frequent punctures and CPI has not been established. In the
current study, an increased risk for CPI in the patients who
received more cycles of chemotherapy was not observed.
This study consisted of Chinese cancer patients and has a
relatively larger sample size compared with other similar
studies. The authors hope this study could offer important
information to prevent Asian patients from CPI. In conclu-
sion, infection remains a challenging issue for total
implantable central venous ports. Implementation of an
insertion bundle for preventing central line-associated
bloodstream infections is warranted, especially for those
patients with hematological and head and neck cancers, as
well as for patients receiving chemotherapy in the meta-
static settings.Acknowledgments
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